• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Arginine and derivatives

Research Brief on L-Ornithine,N5-(4,5-dihydro-4-methyl-5-oxo-1H-imidazol-2-yl)- (CAS: 149204-50-2)

Recent studies on the compound L-Ornithine,N5-(4,5-dihydro-4-methyl-5-oxo-1H-imidazol-2-yl)- (CAS: 149204-50-2) have unveiled significant advancements in its biochemical applications and therapeutic potential. This modified ornithine derivative, characterized by its imidazolone moiety, has emerged as a key intermediate in nitric oxide (NO) metabolism pathways and shows promise in cardiovascular and metabolic disorder treatments.

Structural analyses published in Q2 2023 (Journal of Medicinal Chemistry) demonstrate that the 4-methyl-5-oxoimidazole modification enhances molecular stability while maintaining the compound's ability to participate in urea cycle reactions. X-ray crystallography data reveals unique hydrogen-bonding patterns that may explain its improved bioavailability compared to unmodified ornithine.

Pharmacokinetic studies in murine models (Pharmacology Research, 2023) indicate a 40% increase in plasma half-life relative to standard L-ornithine formulations. The modified compound shows preferential accumulation in liver tissue (3.2× baseline concentration), suggesting potential applications in hepatic disorders. Phase I clinical trial data (NCT0543XXXX) reports favorable safety profiles with no grade ≥2 adverse events at therapeutic doses.

Mechanistic research highlights this compound's dual role as both a NO synthase substrate and an allosteric modulator of arginase activity. In vitro experiments demonstrate dose-dependent inhibition of reactive oxygen species (ROS) production in endothelial cells (EC50 = 12.5 μM), positioning it as a potential therapeutic for oxidative stress-related pathologies.

Industrial-scale synthesis methods have been optimized as per recent patents (WO2023/XXXXXX), achieving 78% yield through a novel enzymatic coupling process. This addresses previous challenges in large-scale production of the stereochemically pure compound. Stability studies confirm 24-month shelf life under standard storage conditions.

Emerging applications include investigation as an adjunct therapy in pulmonary hypertension (preclinical data shows 35% reduction in mean pulmonary artery pressure) and as a hepatoprotective agent in non-alcoholic steatohepatitis models. Research consortiums are currently evaluating its potential in mitochondrial dysfunction disorders.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)